Biote Corp. Finalizes Interim CEO Compensation with Significant Equity Grant
Summary
Biote Corp. disclosed the compensation package for its Interim CEO, Robert Peterson, including a $658,800 base salary, substantial annual incentive eligibility, and a stock option grant representing 0.56% of outstanding shares.
Key Events
-
Interim CEO Compensation Finalized
Biote Corp. filed an amendment to disclose the compensation arrangements for Robert Peterson, appointed Interim Chief Executive Officer on June 8, 2026.
-
Significant Base Salary Approved
Mr. Peterson's amended employment agreement includes an annual base salary of $658,800, with eligibility for annual incentive compensation up to 72.5% of his base salary.
-
Substantial Equity Grant
He was granted a stock option award to purchase shares equal to 0.56% of the company's outstanding common stock, with an additional option for the same amount if appointed non-interim CEO.
-
Generous Severance Terms
The agreement includes 12 months of base salary and health insurance premiums upon termination without cause, with enhanced benefits during a change in control period.
Analysis
This amendment provides the previously undisclosed compensation details for Interim CEO Robert Peterson, who was appointed on June 8, 2026. The package includes a high base salary and a significant equity grant (0.56% of outstanding shares), along with generous severance terms. Given the company's recent reports of declining revenue and EBITDA, this substantial compensation for an interim role could raise concerns about cash burn and potential dilution for existing shareholders.
At the time of this filing, BTMD was trading at $2.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.3M. The 52-week trading range was $1.27 to $4.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.